Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Autonomics and Hypertension
•
Cardio-Obstetrics
•
Primary Care
What is your preferred beta blocker for management of arrhythmias and/or HTN during pregnancy?
Answer from: at Academic Institution
Per ACOG guidelines, labetalol is the main beta-blocker for the treatment of hypertension and other cardiovascular indications in pregnancy.
Comments
at Cardiovascular Institute At Beth Israel Deaconess Medical Center
What about LongQT?
at Barnabas Health
Nadolol.
13826
13834
Sign In
or
Register
to read more
25074
Related Questions
Is it a good practice to prescribe clonidine to take as needed for occasional severe blood pressure elevations?
Do you discontinue amlodipine or use an alternative approach to manage peripheral edema when it occurs as a side effect of the medication?
Do you recommend transitioning elderly patients from thiazide diuretics to alternative agents when managing hypertension given the increased concern for hyponatremia in this patient population?
Do you counsel patients to take antihypertensives at specific times of day to maximize efficacy or minimize side effects?
If a pregnant patient with a mechanical heart valve takes warfarin throughout her pregnancy, what are the chances that the fetus will be harmed?
Do you take any special considerations when working up a pregnant patient for secondary causes of hypertension?
How do you consider and approach transition to hospice in a patient with HFrEF who does not appear to tolerate GDMT?
How do you recommend mitigating the risks of using beta blocker and clonidine therapy in combination for management of hypertension?
When do you think physicians should seriously consider prescribing PCSK9 inhibitors for the prevention of heart attack and stroke in people with ASCVD or diabetes, based on the results of the VESALIUS-CV trial?
Would you prescribe a GLP-1 receptor agonist for an obese patient with low to moderate cardiovascular risk but a high CAC score?
What about LongQT?
Nadolol.